Should physicians withhold highly active antiretroviral therapies from HIV-AIDS patients who are thought to be poorly adherent to treatment?

AIDS

Volumn 15, Issue 2, 2001, Pages 153-159

  Sollitto, S ^a   Mehlman, M ^a   Youngner, S ^a   Lederman, M M ^a  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

Adherence to treatment; AIDS; Highly active antiretroviral therapy; HIV

Indexed keywords

ANTIRETROVIRUS AGENT; ANTIVIRUS AGENT; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; COST EFFECTIVENESS ANALYSIS; DRUG WITHDRAWAL; HEALTH CARE POLICY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; PATIENT COMPLIANCE; PRIORITY JOURNAL; RESOURCE ALLOCATION; REVIEW; VIRUS TRANSMISSION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; HEALTH POLICY; HIV INFECTIONS; HUMANS; PHYSICIAN'S ROLE; TREATMENT REFUSAL;

EID: 0035951446     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200101260-00003     Document Type: Review

References (72)

1. Positive effects of combined antiretroviral therapy on CD4+T cell homeostasis and function in advanced HIV disease
2. Immunologic responses associated with 12 weeks of combination antiretroviral therapy consisting of zidovudine, lamivudine, and ritonavir: Results of AIDS Clinical Trials Group Protocol 315
3. Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration
4. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection
5. The changing spectrum of HIV mortality: Analysis of 249 deaths from 1995-1999
6. Randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: The INCAS Trial
7. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir
8. Human immunodeficiency virus 1 protease inhibitors in clinical practice: Predictors of virological outcome
9. Incidence and predictors of virologic failure to indinavir (IDV) or/and ritonavir (RTV) in an urban health clinic
10. HIV-1 protease inhibitors: A review for clinicians
11. Ethical challenges posed by clinical progress in AIDS
12. Who defines futility?
13. Pipes, colanders and leaky buckets: Reflections on the futility debate
14. Futility: Is definition the problem?
15. Futility: A concept in search of a definition
16. Delayed immuno-logic deterioration among patients who virologically fail protease inhibitor-based therapy
17. A critical technico-ethical dilemma of current medicine
18. Health care resources, allocation of
19. Should a patient who attempted suicide receive a liver transplant?
20. Risky business. [Clinical problem-solving]
21. The noncompliant substance abuser. [Case study and commentaries]
22. Denying treatment to the noncompliant patient
23. Physicians and futile care: Using ethics committees to slow the momentum
24. Medically futile care: The role of the physician in setting limits
25. Public health implications of antiretroviral therapy and HIV drug resistance
26. Sexual transmission of an HIV-1 variant resistant to multiple reverse-transcriptase and protease inhibitors
27. Prevalence of primary HIV drug resistance among seroconverters during an explosive outbreak of HIV infection among injecting drug users
28. Transmission of antiretroviral-drug-resistant HIV-1 variants
29. Transmission and prevalence of HIV resistance among treatment-naive subjects
30. High frequency of antiretroviral drug resistance in HIV-1 from recently infected therapy naive individuals
31. Prevalence of HIV-1 resistant to antiretroviral drugs in 81 individuals newly infected by sexual contact or injecting drug use
32. Drug resistance genotypes from plasma virus of HIV-infected patients failing combination drug therapy
33. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection
34. Severe hepatitis in three AIDS patients treated with indinavir
35. Anaphylaxis after rechallenge with abacavir
36. Virological efficacy and plasma drug concentrations of nelfinavir plus saquinavir as salvage therapy in HIV-infected patients refractory to standard triple therapy
37. Resistance mutations as predictor of response to salvage therapy
38. Randomized trial of abacavir (ABC) and nelfinavir (NEV) in combination with efavirenz (EFV) and adefovir Dipivoxi1 (ADV) as salvage therapy in patients with virologic failure receiving indinavir (IDV)
39. The magnitude of compliance and noncompliance
40. Psychological impact of HIV disease and implications for intervention
41. Behavioral and psychosocial predictors of compliance in HIV asymptomatic and symptomatic
42. Adherence to antiretroviral therapy in HIV disease
43. Adherence to antiretroviral and pneumocystis prophylaxis in HIV disease
44. Adherence to protease inhibitor (PI) therapy in clinical practice: Usefulness of demographics, attitudes and knowledge as predictors
45. Maintaining protease inhibitor therapy in a clinic setting
46. Diagnosing potential noncompliance: Physicians' ability in a behavioral dimension of medical care
47. Patients' cooperation with a medical regimen
48. Is this patient taking the treatment as prescribed?
49. Introducing medical students to medication noncompliance
50. Determinants of compliance with antiretroviral therapy in patients with human immunodeficiency virus: Prospective assessment with implications for enhancing compliance
51. Zidovudine adherence among individuals with HIV infection
52. Protease inhibitors (PI) in the HIV+ homeless and marginally housed (H/M): Good adherence but rarely prescribed
53. HIV-infected homeless and marginally housed (H/M) patients adhere to and receive early virologic benefit from protease inhibitors
54. Protease inhibitors are associated with viral load suppression in HIV+ homeless and marginally housed adults
55. Relationship between adherence to HAART and disease state
56. Preliminary results of a compliance study within CPCRA 007 combination nucleoslde study (NuCombo)
57. Adherence to complex combination antiretroviral therapies by HIV-positive drug abusers
58. Highly active antiretroviral therapy in a large urban clinic: Risk factors for virologic failure and adverse drug reactions
59. Antecedents of adherence to medical recommendations: Results from the Medical Outcomes Study
60. HIV outpatient adherence: Relation of disease status to appointment-keeping
61. Protease inhibitors in the homeless
62. Rethinking nonadherence: Historical perspectives on triple-drug therapy for HIV disease
63. Antiretroviral therapy in adults: Updated recommendations of the International AIDS Society - USA Panel
64. Predicting antiviral compliance: Physicians' responsibilities vs patients' rights
65. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial
66. Adherence and antiretroviral therapy in injection drug users
67. When should we delay highly active antiretroviral therapy?